Live Breaking News & Updates on Chronic disease research

Stay informed with the latest breaking news from Chronic disease research on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Chronic disease research and stay connected to the pulse of your community

Multiple sclerosis has subtypes with different best treatments: study

While more study is needed, blood tests of newly diagnosed multiple sclerosis patients showed distinct differences and progression.

Germany , German , Heinz-wiendl , Genentech-ocrevus , Sanofi-genzyme-lemtrada , Alberto-ascherio , Lebron-james , Science-translational , Sanofi-genzyme , Chronic-disease-research ,

Stillman College Is Creating the Chronic Disease Research and Training Shared Facility | The Journal of Blacks in Higher Education

Stillman College Is Creating the Chronic Disease Research and Training Shared Facility | The Journal of Blacks in Higher Education
jbhe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jbhe.com Daily Mail and Mail on Sunday newspapers.

Stillman-college , Alabama , United-states , University-of-alabama , Rosiana-gray , Rosianna-gray , Chronic-disease-research , Stillman-chronic-disease-research , Us-department-of-health , Stillman-college-in-tuscaloosa , Human-services , Black-stillman-college

USGrants.org Releases Monthly Report on Grants for Businesses in August 2023

USGrants.org Releases Monthly Report on Grants for Businesses in August 2023
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

United-states , Automotive-service-providers , Consumer-protection-companies , Power-generation-companies , Trucking-service-providers , Hunting-service-providers , Nutrition-companies , Heating-companies , Training-services , Insurance-companies , Innovation-research-organizations

USGrants.org Releases Monthly Report on Grants for Businesses in July 2023

USGrants.org Releases Monthly Report on Grants for Businesses in July 2023
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

United-states , Sacramento , California , Telecommunication-services , Nuclear-forensics , Renewable-energy-services , Marketing-service-providers , Transportation-services , Community-services , Reproductive-health-organizations , Power-generation-companies

Diabetes Decision Tool Yields Benefit in Low-Resource Clinics

Adding a computerized clinician support system to diabetes care improved the cardiovascular health of patients with diabetes.

China , United-states , Jiang-he , Hunan , Xiamen , Fujian , Chinese , Anne-peters , Los-angeles , Elbert-huang , Diabetes-complication-control-in-community-clinics , Tulane-university

Can SGLT2 and GLP1 Agents Be Cost-Effective First-Line Diabetes Treatments?

Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes.

United-states , American , Neda-laiteerapong , European-association-for-the-study-of-diabetes , Nutrition-examination-survey , National-health , University-of-chicago-department-medicine , National-institute-on , Chronic-disease-research , American-diabetes-association , General-internal-medicine , Chicago-department

Can SGLT2 and GLP1 Agents Be Cost-Effective First-Line Diabetes Treatments?

Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes.

United-states , American , Neda-laiteerapong , European-association-for-the-study-of-diabetes , Nutrition-examination-survey , National-health , University-of-chicago-department-medicine , National-institute-on , Chronic-disease-research , American-diabetes-association , General-internal-medicine , Chicago-department

Newer Drugs Not Cost-Effective for First-Line Diabetes Therapy

Costs of SGLT2 inhibitors and GLP-1 receptor agonists 'need to be lowered substantially' to improve health outcomes and prevent health disparities in patients with type 2 diabetes, say researchers.

Illinois , United-states , University-of-chicago , United-kingdom , Jing-choi , Neda-laiteerapong , Nutrition-examination-survey , National-health , Drug-administration , Chronic-disease-research , Medscape-medical-news , Affordable-insulin-now-act

Clinical trials of new treatments for COVID-19 often do not include vulnerable populations

Clinical trials of new treatments for COVID-19 often do not include vulnerable populations
Studies examining the effectiveness of treatments for COVID-19 often do not include the very populations hardest hit by the disease, according to a new review by University of Chicago Medicine researchers.
The findings, based on an analysis of all US COVID-19 treatment trials registered on ClinicalTrials.gov, were published Jan. 27 in the
Journal of General Internal Medicine.
This study highlights the blind spot in how clinical trials are done in the United States. Researchers, hospitals and pharmaceutical companies need to think hard about their commitment to improving the health of all people."

United-states , Americans , American , Anna-volerman , Sukarn-chokkara , Neda-laiteerapong , Siddhi-ramesh , Emily-henderson , American-community , University-of-chicago , University-of-chicago-pritzker-school-medicine , University-of-chicago-medicine

Most vulnerable often overlooked in clinical trials of new treatments for COVID-19

E-Mail
Studies examining the effectiveness of treatments for COVID-19 often do not include the very populations hardest hit by the disease, according to a new review by University of Chicago Medicine researchers.
The findings, based on an analysis of all US COVID-19 treatment trials registered on ClinicalTrials.gov, were published Jan. 27 in the
Journal of General Internal Medicine.
"This study highlights the blind spot in how clinical trials are done in the United States," said senior author Neda Laiteerapong, MD, MS, a general internist and associate director of the Center for Chronic Disease Research and Policy at the University of Chicago. "Researchers, hospitals and pharmaceutical companies need to think hard about their commitment to improving the health of all people."

United-states , Americans , American , Anna-volerman , Sukarn-chokkara , Neda-laiteerapong , Siddhi-ramesh , American-community , University-of-chicago , University-of-chicago-pritzker-school-medicine , University-of-chicago-medicine , Chronic-disease-research